University of Illinois College of Medicine, Chicago, Illinois, USA.
Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Exp Dermatol. 2022 Apr;31(4):485-497. doi: 10.1111/exd.14541. Epub 2022 Mar 1.
Aryl hydrocarbon receptor (AHR)/nuclear factor-erythroid 2-related factor 2 (NRF2) modulation is emerging as novel targets in the treatment of atopic dermatitis and other inflammatory skin disorders. Agonist activation of this pathway has downstream effects on epidermal barrier function, immunomodulation, oxidative stress reduction and cutaneous microbiome modulation. Tapinarof, a dual agonist of the AHR/NRF2 signalling pathway, has shown promise in phase 2 trials for atopic dermatitis. In this review, we summarize current knowledge of the AHR/NRF2 pathway and implications in skin disease process. We also review the therapeutic potential of current AHR agonists and propose future directions to address knowledge gaps.
芳烃受体（AHR）/红细胞生成素相关因子 2（NRF2）的调节作用正成为特应性皮炎和其他炎症性皮肤病治疗的新靶点。该途径的激动剂激活对表皮屏障功能、免疫调节、氧化应激减少和皮肤微生物组调节具有下游效应。双激动剂 Tapinarof 已在特应性皮炎的 2 期临床试验中显示出前景。在这篇综述中，我们总结了 AHR/NRF2 通路的现有知识及其在皮肤疾病过程中的意义。我们还回顾了目前 AHR 激动剂的治疗潜力，并提出了未来解决知识空白的方向。
